- Current report filing (8-K)
April 03 2009 - 3:05PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to
Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 3,
2009
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant as
specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
|
|
|
|
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Section 7 Regulation FD
Item 7.01 Regulation FD Disclosure.
On April 3,
2009, Allos Therapeutics, Inc., a Delaware corporation (the Company),
issued a press release announcing the closing of its previously reported
underwritten public offering of 7,750,000 shares of its common stock at the
public offering price of $6.30 per share.
The Company has granted the underwriter a 30-day option to purchase up
to an additional 1,162,500 shares to cover over-allotments, if any. The press release is attached hereto as Exhibit 99.1
and incorporated herein by reference.
In
accordance with General Instruction B.2. of Form 8-K, the information
presented under this Item 7.01 and attached as Exhibit 99.1 shall not
be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such a filing.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
99.1
|
|
Press Release, dated
April 3, 2009, entitled Allos
Therapeutics Announces Closing of Common Stock Offering.
|
2
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:
|
April 3,
2009
|
|
|
|
|
|
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
April 3, 2009, entitled Allos
Therapeutics Announces Closing of Common Stock Offering.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024